Wednesday, October 22, 2008: 11:30 AM
Columbus A-C (Hyatt Regency Penns Landing)
Poster Number Acronyms
COMPARISONS OF PRIMARY CARE PHYSICIANS' INITIALLY PREFERRED COLORECTAL CANCER SCREENING STRATEGIES WITH THOSE DERIVED FROM A MULTI-CRITERIA ANALYSIS
James G. Dolan, MD1, Jeroan Allison, MD2, Emily Boohaker, MD2 and Thomas F. Imperiale, MD3, (1)Unity Health System & the University of Rochester, Rochester, NY, (2)University of Alabama at Birmingham, Birmingham, AL, (3)Indiana University School of Medicine, Indianapolis, IN
HOW WELL DO CLINICIANS INTERPRET CLINICAL EVIDENCE?
James G. Dolan, MD1, Jeroan Allison, MD2, Emily Boohaker, MD2 and Thomas F. Imperiale, MD3, (1)Unity Health System & the University of Rochester, Rochester, NY, (2)University of Alabama at Birmingham, Birmingham, AL, (3)Indiana University School of Medicine, Indianapolis, IN
DESIGNING EFFICIENT LUNG CANCER SCREENING PROGRAMS: ROLES OF ADHERENCE, ELIGIBILITY, AND SCREEN FREQUENCY
Lauren E. Cipriano, BSc., BA, Chung Yin Kong, PhD, Elyse R. Park, PhD, G. Scott Gazelle, MD, MPH, PhD and Pamela M. McMahon, Ph.D., Massachusetts General Hospital, Boston, MA
HEALTH AND ECONOMIC IMPACT OF HPV 16 AND 18 VACCINATION IN GAVI-ELIGIBLE COUNTRIES
Sue J. Goldie, MD, MPH1, Meredith O'Shea, MA1, Nicole G. Campos, MSc2, Mireia Diaz-Sanchis, MSc3, Steven G. Sweet, MBA1 and Sun-Young Kim, PhD1, (1)Harvard School of Public Health, Boston, MA, (2)Harvard University, Boston, MA, (3)Catalan Institute of Oncology, Hospitalet de Llobregat, Spain
IMPACT OF HUMAN PAPILLOMAVIRUS (HPV) VACCINATION IN CHINA: COMPARATIVE COST-EFFECTIVENESS BETWEEN AREAS OF HETEROGENEOUS RISK
Jesse D. Ortendahl, BS1, Mireia Diaz-Sanchis, MSc2, Sue J. Goldie, MD, MPH1, Carol Levin, PhD3 and Jane J. Kim, PhD1, (1)Harvard School of Public Health, Boston, MA, (2)Catalan Institute of Oncology, Hospitalet de Llobregat, Spain, (3)Path, Seattle, WA
HEALTH AND ECONOMIC IMPACT OF HPV 16 AND 18 VACCINATION IN LATIN AMERICA AND THE CARIBBEAN
Sue J. Goldie, MD, MPH1, Mireia Diaz-Sanchis, MSc2, Steven G. Sweet, MBA1, Dagna Constenla, PhD, MPA3, Nelson Alvis, MD, PhD, MPH4, Jon Andrus, MD, MPH5 and Sun-Young Kim, PhD1, (1)Harvard School of Public Health, Boston, MA, (2)Catalan Institute of Oncology, Hospitalet de Llobregat, Spain, (3)Sabin Vaccine Institute, Denver, CO, (4)Universidad de Cartagena, Colombia, Colombia, (5)Pan American Health Organization, Washington, DC
BAYESIAN GENERALIZED LINEAR MODELS FOR META-ANALYSIS OF DIAGNOSTIC TESTS
Yan Xing, MD, MS, PhD1, Janice N. Cormier, MD, MPH1, Asha S. Kapadia, PhD2, John M. Swint, PhD2 and Claudia Pedroza, PhD2, (1)The University of Texas M.D. Anderson Cancer Center, Houston, TX, (2)The University of Texas School of Public Health, Houston, TX
THE COST-EFFECTIVENESS OF RADIOFREQUENCY CATHETER ABLATION FOR THE TREATMENT OF ATRIAL FIBRILLATION: RESULTS FROM A BAYESIAN EVIDENCE SYNTHESIS AND VALUE OF INFORMATION ANALYSIS
Stephen Palmer, MSc1, Claire McKenna, PhD1, Mark Rogers1, Duncan Chambers1, Chris Pepper2, Derick Todd3 and Nerys Woolacott, PhD1, (1)University of York, York, United Kingdom, (2)Leeds Teaching Hospitals, Leeds, United Kingdom, (3)Liverpool NHS Trust, Liverpool, United Kingdom
PRE-TRIAL MODELING FOR COST-EFFECTIVENESS: ISSUES OF DESIGN AND POPULATION. AN EXAMPLE IN HEART FAILURE
Elisabeth A.L. Fenwick, PhD1, Paula K. Lorgelly, PhD1, Pardeep S. Jhund, MBChB, MRCP1, Sanjay K. Gandhi, PhD2 and Andrew Briggs, DPhil1, (1)University of Glasgow, Glasgow, United Kingdom, (2)AstraZeneca, Wilmington, DE
ORGAN ALLOCATION IN KIDNEY PAIRED DONATION WITH NEVERENDING CHAINS
Sommer Gentry, PhD1, Robert A. Montgomery, MD, DPhil2 and Dorry L. Segev2, (1)United States Naval Academy, Baltimore, MD, (2)Johns Hopkins Medical Institutions, Baltimore, MD
IDENTIFYING SIGNIFICANT PREDICTORS OF HIGH HEALTHCARE COSTS IN DIABETES USING A DECISION TREE APPROACH
Michael B. Nichol, PhD1, Tara K. Knight, PhD1, Joanne Wu, MS1, Jack Mahoney, MD2 and Christine Berman, PhD2, (1)University of Southern California, Los Angeles, CA, (2)Pitney Bowes, Stamford, CT
PRACTICAL DEPRESSION SCREENING IN ASSISTED LIVING: FIVE METHODS COMPARED TO GOLD STANDARD DIAGNOSES
Lea Watson, MD, MPH1, Sheryl Zimmerman, PhD2, Lauren Cohen, MA2 and Rosalie Dominik, Dr.PH2, (1)UNC -Chapel Hill School of Medicine, Chapel Hill, NC, (2)UNC School of Medicine, Chapel Hill, NC
TEN MILLION QUALITY ADJUSTED LIFE YEARS LOST DUE TO KNEE OSTEOARTHRITIS IN THE US ELDERLY POPULATION: THE ROLE OF OBESITY
Elena Losina, PhD1, Rochelle P. Walensky, MD, MPH2, Holly L. Holt1, William M. Reichmann, MA1, Michael P. Raybman1, Courtenay L. Kessler, MPH1, Daniel H. Solomon, MD, MPH1, Joanne M. Jordan, MD, MPH3, David J. Hunter, PhD, MBBS4, Miriam G. Cisternas, MA5, A. David Paltiel, PhD6 and Jeffrey N. Katz, MD, MS1, (1)Brigham and Women's Hospital, Boston, MA, (2)Massachusetts General Hospital, Boston, MA, (3)University of North Carolina, Chapel Hill, NC, (4)New England Baptist Hospital, Boston, MA, (5)MGC Data Services, Carlsbad, CA, (6)Yale School of Medicine, New Haven, CT
QUANTIFYING THE BENEFIT OF EARLY LIVING-DONOR RENAL TRANSPLANTATION WITH A SIMULATION MODEL OF THE DUTCH RENAL REPLACEMENT THERAPY POPULATION
Ylian S. Liem, MD, MSc1, John B. Wong, MD2, Wolfgang C. Winkelmayer, MD, ScD3, Willem Weimar, MD, PhD1, Jack F.M. Wetzels, MD, PhD4, Frank Th. De Charro, PhD5, Guido C. Kaandorp, MSc1, Theo Stijnen, PhD6 and M.G. Myriam Hunink, MD, PhD1, (1)Erasmus MC - University Medical Center Rotterdam, Rotterdam, Netherlands, (2)Tufts Medical Center, Tufts University School of Medicine, Boston, MA, (3)Brigham & Women's Hospital, Harvard Medical School, Boston, MA, (4)Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, (5)Dutch End Stage Renal Disease Registry RENINE, Rotterdam, Netherlands, (6)Leiden University Medical Center, Leiden, Netherlands
CAN VOI ANALYSIS BE USED FOR SETTING GOVERNMENT RESEARCH AGENDAS AND PRIORITIES?: EXPERIENCE TO DATE FROM A LARGE PROVINCE-WIDE INITIATIVE USING AN ITERATIVE VOI ANALYSIS FRAMEWORK
Ron Goeree, MA1, Morgan Lim, MA1, Daria J. O'Reilly, PhD, MSc1, Jean-Eric Tarride, PhD, MA1, Feng Xie, PhD1, James M. Bowen, BScPhm, MSc1, Gord Blackhouse, MSc.2 and Robert Hopkins, MA1, (1)McMaster University, Hamilton, ON, Canada, (2)McMaster Unviersity, Hamilton, ON, Canada
ECONOMIC EVALUATION STUDIES SUBMITTED TO INFORM CANCER DRUG FUNDING DECISIONS: A CLOSER LOOK AT THE QUALITY AND LIMITATIONS
Jean Hai Ein Yong, MASc1, Sandjar Djalalov, PhD1 and Jeffrey Hoch, PhD2, (1)Cancer Care Ontario, Toronto, ON, Canada, (2)St. Michael's Hospital, University of Toronto, Toronto, ON, Canada
A PARTIALLY OBSERVABLE MARKOV DECISION PROCESS TO DETERMINE OPTIMAL PSA BASED BIOPSY THRESHOLDS FOR PROSTATE CANCER
Jingyu Zhang, MS1, Hari Balasubramanian, PhD2, Nilay D. Shah, PhD2, Brant Inman, MD2 and Brian T. Denton, PhD1, (1)North Carolina State University, Raleigh, NC, (2)Mayo Clinic, Rochester, MN
A COMPREHENSIVE NATURAL HISTORY MODEL OF PRESSURE ULCER TO ESTIMATE THE CLINICAL IMPACT OF PREVENTION AND TREATMENT OPTIONS
Ba Pham, MSc1, Wendong Chen, MD1, Márcio Machado, PhD1, Walter Wodchis, PhD1, Tara Gomes, MHSc2, Anita Stern, PhD1, Beate Sander, RN, MBA, MEcDev1, Hla-Hla Thein, MD, MPH, PhD3, Nancy Sikich, MSc2, Ahmed Bayoumi, MD, MSc1 and Murray Krahn, MD, MSc1, (1)University of Toronto, Toronto, ON, Canada, (2)Medical Advisory Secretariat, Ontario Ministry of Health and Long-Term Care, Toronto, ON, Canada, (3)University of New South Wales, Sydney, Australia
A NEURAL NETWORK-BASED DECISION MAKING PROCESS TO CLASSIFY LEUKEMIA BLOOD SAMPLES
Melvin Ayala, PhD, Malek Adjouadi, PhD, Mercedes Cabrerizo, PhD, Nuannuan Zong, PhD and Armando Barreto, PhD, Florida International University, Miami, FL
SIMULATION OF SECONDARY COLORECTAL CANCER UNDER COLONOSCOPY SCREENINGS
Fatih S. Erenay, MS1, Oguzhan Alagoz, PhD1, Ritesh Banerjee, PhD2 and Robert R. Cima, MD2, (1)University of Wisconsin, Madison, WI, (2)Mayo Clinic, Rochester, MN
COMPARISON OF MATHEMATICAL AND BEHAVIOURAL ELICITATION APPROACHES: APPLICATION USING A DECISION MODEL FOR TOPICAL NEGATIVE PRESSURE (TNP) THERAPY FOR PRESSURE ULCERS
Laura Bojke, MSc, Marta Soares, MSc, Jo Dumville, PhD and Karl Claxton, PhD, MSc, BA, University of York, York, United Kingdom
![[ Visit Client Website ]](images/banner.gif)